MDMA-Assisted Therapy Demonstrates Significant Reductions in Post-Traumatic Stress Disorder Symptoms in Phase 3 Study

Study results could lead to an FDA approval for MDMA to treat post-traumatic stress disorder by the end of 2023.

Related Keywords

Kelan Thomas ,Vitalii Vodolazskyi ,Rick Doblin ,Ismail Lourido Ali ,Multidisciplinary Association For Psychedelic ,Multidisciplinary Association For Psychedelic Studies ,Touro University California College Of Pharmacy ,Public Benefit Corporation ,Multidisciplinary Association ,Psychedelic Studies ,Benefit Corporation ,New Drug Application ,Open Science ,Open Books ,Sheehan Disability Scale ,Pharmacy Times ,Touro University California College ,Successful Confirmatory Phase ,Assisted Therapy ,